What we could do now: Molecular pathology of colorectal cancer

Journal of Clinical Pathology - Molecular Pathology

Volumn 54, Issue 4, 2001, Pages 206-214

  Houlston, R S ^a  

^a INSTITUTE OF CANCER RESEARCH   (United Kingdom)

Author keywords

Colorectal cancer; Genes; Prognosis

Indexed keywords

PROTEIN P27; PROTEIN P53;

ALLELE; CANCER SUSCEPTIBILITY; CARCINOGENESIS; COLORECTAL CANCER; CONFERENCE PAPER; GENOTYPE; MICROSATELLITE INSTABILITY; MOLECULAR GENETICS; ONCOGENE K RAS; PRIORITY JOURNAL; PROGNOSIS;

ADENOCARCINOMA; ADENOMA; BASE PAIR MISMATCH; CHROMOSOMES, HUMAN, PAIR 17; CHROMOSOMES, HUMAN, PAIR 18; COLORECTAL NEOPLASMS; DISEASE PROGRESSION; DNA REPAIR; GENE DELETION; GENES, APC; GENES, DCC; GENES, P53; GENES, RAS; GENETIC MARKERS; HAMARTOMA; HUMANS; MICROFILAMENT PROTEINS; MUSCLE PROTEINS; MUTATION; PROGNOSIS;

EID: 0034907056     PISSN: 13668714     EISSN: None     Source Type: Journal    
DOI: 10.1136/mp.54.4.206     Document Type: Conference Paper

References (153)

1. Colorectal carcinoma
2. Management and survival of patients with adenocarcinoma of the colon and rectum: A national survey of the commission on cancer
3. The spread of cancer and its effect on prognosis
4. A new prognostic classification of rectal cancer
5. Growth rate of hepatic metastases in colorectal cancer
6. A genetic model for colorectal tumorigenesis
7. APC mutations occur early during colorectal tumorigenesis
8. Identification and characterization of the familial adenomatous polyposis coli gene
9. Identification of FAP locus genes from chromosome 5q21
10. Somatic mutations of the APC gene in colorectal tumors: Mutation cluster region in the APC gene
11. Chromosome 5 allele loss in human colorectal carcinomas
12. Characteristics of somatic mutation of the adenomatous polyposis coli gene in colorectal tumours
13. Dimer formation by an N terminal coiled coil in the APC protein
14. The tumour suppressor gene product APC blocks cell cycle progression from G0/G1 to S phase
15. Association of the APC tumor suppressor protein with catenins
16. Association of the APC gene product with beta catenin
17. Loss of apc protein expressed by human colonic epithelial cells and the appearance of a specific low molecular weight form is associated with apoptosis in vitro
18. The tumour suppressor APC product is associated with cell adhesion
19. The APC gene product associates with microtubules in vivo and promotes their assembly in vitro
20. Mutations of a mutS homolog in hereditary nonpolyposis colorectal cancer
21. The human mutator gene homolog MSH2 and its association with hereditary nonpolyposis colon cancer
22. Clues to the pathogenesis of familial colorectal cancer
23. Germ-line msh6 mutations in colorectal cancer families
24. Mismatch repair gene defects in sporadic colorectal cancers with microsatellite instability
25. The mutation rate and cancer
26. Clinicopathological characteristics of colorectal carcinoma complicating ulcerative colitis
27. Genetic pathways in colorectal cancer
28. Common occurrence of APC and K ras mutation in the spectrum of colitis associated neoplasias
29. Adenomatous polyposis coli gene mutations in ulcerative colitis associated dysplasias and cancers versus sporadic colon neoplasms
30. Mutations in the p53 gene: An early marker of neoplastic progression in ulcerative colitis
31. Non allelic heterogeneity of familial adenomatous polyposis
32. Clinical and molecular features of the hereditary mixed polyposis syndrome
33. A serine/threonine kinase gene defective in Peutz-Jeghers syndrome
34. Mutations in the SMAD4/DPC4 gene in juvenile polyposis
35. Germline mutations of the PTEN gene in Cowden disease, an inherited breast and thyroid cancer syndrome
36. Familial giant hyperplastic polyposis predisposing to colorectal cancer a new hereditary bowel cancer syndrome
37. Regression phenomenon in familial polyposis
38. Sulindac and polyp regression
39. The ras gene family and human carcinogenesis
40. Somatic APC and K ras codon 12 mutations in aberrant crypt foci from human colons
41. Mutant K ras in apparently normal mucosa of colorectal cancer patients. Its potential as a biomarker of colorectal tumorigenesis
42. Aberrant crypt foci and K ras mutations: Earliest recognised players or innocent bystanders in colon carcinogenesis?
43. Role of aberrant crypt foci in understanding the pathogenesis of colon cancer
44. Allelic loss of chromosome 18q and prognosis in colorectal cancer
45. Genetic alterations during colorectal tumour development
46. Identification of a gene located at chromosome 5q21 that is mutated in colorectal cancers
47. Loss of heterozygosity of MCC is not associated with mutation of the retained allele in sporadic colorectal cancer
48. Homozygous deletion map at 18q21.1 in pancreatic cancer
49. Cancer. p53, guardian of the genome
50. The tumor suppressor p53
51. Stabilised p53 facilitates aneuploid clonal divergence in colorectal cancer
52. Somatic spectrum of cancer associated single basepair substitutions in the p53 gene is determined mainly by endogenous mechanisms of mutation and by selection
53. p53 gene mutations occur in combination with 17p allelic deletions as late events in colorectal tumorigenesis
54. Expression of p53 and allelic loss in colorectal carcinoma
55. Immunohistochemical study of p53 expression in microwave fixed, paraffin embedded sections of colorectal carcinoma and adenoma
56. The FHIT gene, spanning the chromosome 3p14.2 fragile site and renal carcinoma associated t(3 ,8) breakpoint, is abnormal in digestive tract cancers
57. Mutations and altered expression of p16INK4 in human cancer
58. Inactivation of the CDKN2/p16/MTS1 gene is frequently associated with aberrant DNA methylation in all common human cancers
59. Methylation of the 5′CpG island of the p16/CDKN2 tumor suppressor gene in normal and transformed human tissues correlates with gene silencing
60. Human colorectal cancer: High frequency of deletions at chromosome 1p35
61. Deletion mapping defines different regions in 1p34.2 pter that may harbor genetic information related to human colorectal cancer
62. A study of chromosome 6 allele loss in human colorectal carcinomas
63. Evidence for the presence of two tumor suppressor genes on chromosome 8p for colorectal carcinoma
64. Deletion mapping in colorectal cancer of a putative tumour suppressor gene in 8p22 p21.3
65. Frequent loss of heterozygosity on chromosome 14 occurs in advanced colorectal carcinomas
66. Frequent loss of heterozygosity at telomeric loci on 22q in sporadic colorectal cancers
67. Analysis of mismatch repair genes in hereditary non polyposis colorectal cancer patients
68. Clinical and pathological characteristics of sporadic colorectal carcinomas with DNA replication errors in microsatellite sequences
69. Genomic instability occurs in colorectal carcinomas but not in adenomas
70. Clinico pathological features and p53 expression in left sided sporadic colorectal cancers with and without microsatellite instability
71. Polymerase and variants in RER colorectal tumours
72. MDR1/P glycoprotein expression in colorectal cancer
73. In situ PCR: Protocols and applications
74. Morphoregulatory activities of E cadherin and beta 1 integrins in colorectal tumour cells
75. Plasminogen activator profiles in neoplastic tissues of the human colon
76. Plasminogen activators and inhibitor type 1 in neoplastic colonic tissue from patients with familial adenomatous polyposis
77. The potential roles of nm23 in cancer metastasis and cellular differentiation
78. Overexpression of nm23 H1 and nm23 H2 genes in colorectal carcinomas and loss of nm23 H1 expression in advanced tumour stages
79. Loss of heterozygosity of tumour suppressor gene loci in human colorectal carcinoma
80. Frequency of allele loss of DCC, p53, RBI, WT1, NF1, NM23 and APC/MCC in colorectal cancer assayed by fluorescent multiplex polymerase chain reaction
81. Prognostic significance of the loss of heterozygosity of nm23 h1 and p53 genes in human colorectal carcinomas
82. Positive relationship between expression of CD44 and hepatic metastases in colorectal cancer
83. Allelotype of colorectal carcinomas
84. Recurrent deletions involving chromosomes 1, 5, 17, and 18 in colorectal carcinoma: Possible role in biological and clinical behavior of tumors
85. Survival and acquired genetic alterations in colorectal cancer
86. The significance of allelic deletions and aneuploidy in colorectal carcinoma. Results of a 5 year follow up study
87. Confirmation that chromosome 18q allelic loss in colon cancer is a prognostic indicator
88. Prognostic significance of allelic lost at chromosome 18q21 for stage II colorectal cancer
89. Allelic loss on chromosome 18q as a prognostic marker in stage II colorectal cancer
90. High frequency of allelic deletion on chromosome 17p in advanced colorectal cancer
91. 17q allele loss is associated with lymph node metastasis in locally aggressive human colorectal cancer
92. Genomic alterations (LOH, MI) on chromosome 17q21-23 and prognosis of sporadic colorectal cancer
93. Loss of heterozygosity in 8p is associated with microinvasion in colorectal carcinoma
94. Prognostic value of chromosome 1p allelic loss in colon cancer
95. Loss of heterozygosity on the long arm of chromosome 11 in colorectal tumours
96. Prospective assessment of allelic losses at 4p 14-16 in colorectal cancer: Two mutational patterns and a locus associated with poorer survival
97. Genotypic classification of colorectal adenocarcinoma. Biologic behavior correlates with K ras 2 mutation type
98. Type and number of Ki ras point mutations relate to stage of human colorectal cancer
99. A detailed analysis of K ras point mutations in relation to tumor progression and survival in colorectal cancer patients
100. K ras status does not predict successful hepatic resection of colorectal cancer metastasis
101. Prognostic significance of K ras mutations in colorectal carcinoma
102. Prognostic value of p53 and K ras 2 mutational analysis in stage III carcinoma of the colon
103. Kirsten ras mutations in patients with colorectal cancer: The multi-center "RASCAL" study
104. Biological properties of human c Ha ras1 genes mutated at codon 12
105. Amino acid substitutions at codon 13 of the N ras oncogene in human acute myeloid leukaemia
106. Analysis of the transforming potential of the human H ras gene by random mutagenesis
107. Ha ras proteins exhibit GTPase activity: Point mutations that activate Ha ras gene products result in decreased GTPase activity
108. Biological and biochemical properties of human rash genes mutated at codon 61
109. Comparative biochemical properties of normal and activated human ras p21 protein
110. The DCC protein and prognosis in colorectal cancer
111. Expression of DCC protein in colorectal tumors and its relationship to tumor progression and metastasis
112. Better survival rates in patients with MLH 1-associated hereditary colorectal cancer
113. Prognosis of hereditary nonpolyposis colorectal cancer (HNPCC) and the role of Japanese criteria for HNPCC
114. Microsatellite instability and the role of hMSH2 in sporadic colorectal cancer
115. Differential prognosis of replication error phenotype and loss of heterozygosity in sporadic colorectal cancer
116. Tumor microsatellite instability and clinical outcome in young patients with colorectal cancer
117. Replication error in colorectal carcinoma: Association with loss of heterozygosity at mismatch repair loci and clinicopathological variables
118. Microsatellite instability: Impact on cancer progression in proximal and distal colorectal cancers
119. p53 gene mutation, microsatellite instability and adjuvant chemotherapy: Impact on survival of 388 patients with Dukes' C colon carcinoma
120. Prognostic significance of extensive microsatellite instability in sporadic clinicopathological stage C colorectal cancer
121. Microsatellite instability is a favorable prognostic indicator in patients with colorectal cancer receiving chemotherapy
122. Microsatellite instability in sporadic colorectal cancer is not an independent prognostic factor
123. Increased p53 protein content of colorectal tumours correlates with poor survival
124. Immunohistological p53 staining is of limited value in the staging and prognostic prediction of colorectal cancer
125. Prediction of recurrence in B C stages of colorectal cancer by p53 nuclear overexpression in comparison with standard pathological features
126. p53 nuclear overexpression may not be an independent prognostic marker in early colorectal cancer
127. Prognostic significance of p53 and c erbB 2 immunohistochemical evaluation in colorectal adenocarcinoma
128. Antibodies against p53 are associated with poor prognosis of colorectal cancer
129. Immunohistochemical analysis of p53 in colorectal cancer regarding clinicopathological correlation and prognostic significance
130. Mutations of Ki ras and p53 genes in colorectal cancer and their prognostic significance
131. p53 nuclear overexpression: An independent predictor of survival in lymph node positive colorectal cancer patients
132. Prognostic factors of colorectal cancer: K ras mutation, overexpression of the p53 protein, and cell proliferative activity
133. Correlation of p53 with the clinicopathologic features and prognosis of colorectal adenocarcinoma
134. Relationship among p53, stage, and prognosis of large bowel cancer
135. Prognostic value of p53 overexpression and c Ki ras gene mutations in colorectal cancer
136. Expression of p53 protein in colorectal cancer and its relationship to short term prognosis
137. p53 point mutation and survival in colorectal cancer patients
138. Association of p53 mutations with short survival in colorectal cancer
139. Association of p53 gene and protein alterations with metastases in colorectal cancer
140. Increased incidence of p53 mutations is associated with hepatic metastasis in colorectal neoplastic progression
141. p53 and behaviour of colorectal cancer
142. p53 gene mutations, p53 protein accumulation and compartmentalization in colorectal adenocarcinoma
143. Prognostic significance of p53 overexpression and mutation in colorectal adenocarcinomas
144. Cancer prognostics: Past, present and p27
145. Increased proteasome dependent degradation of the cyclin dependent kinase inhibitor p27 in aggressive colorectal carcinomas
146. Prognostic significance of p27 (kip1) protein expression and spontaneous apoptosis in patients with colorectal adenocarcinomas
147. p27 cell-cycle inhibitor is inversely correlated with lymph node metastases in right-sided colon cancer
148. Prognostic significance of p27 (Kip1) expression in colorectal cancer: A clinico-pathological characterization
149. Allelic loss is heterogeneous throughout the rumor in colorectal carcinoma